Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-11

  Adema, Auke D ^a   Floor, Karijn ^a   Smid, Kees ^a   Honeywell, Richard J ^a   Scheffer, George L ^a   Jansen, Gerrit ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABC pumps; Cytarabine; Gemcitabine; MRP4 (ABCC4); MRP5 (ABCC5); Troxacitabine

Indexed keywords

EID: 84941561919     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-732     Document Type: Article

References (46)

1. Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F, Sandvold ML, Peters GJ: Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 2012, 30: 1908-1916. 10.1007/s10637-011-9756-8
2. Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Laan AC, Schott S, Losekoot N, Honeywell RJ, Peters GJ: Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine. Invest New Drugs 2011, 29(2):248-257. 10.1007/s10637-009-9353-2
3. Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71: 537-592. 10.1146/annurev.biochem.71.102301.093055
4. Chen Z-S, Lee K, Kruh GD: Transport of Cyclic Nucleotides and Estradiol 17-β-d-Glucuronide by Multidrug Resistance Protein 4. J Biol Chem 2001, 276(36):33747-33754. 10.1074/jbc.M104833200
5. de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008, 7(9):3092-3102. 10.1158/1535-7163.MCT-08-0427
6. Deeley RG, Westlake C, Cole SP: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006, 86(3):849-899. 10.1152/physrev.00035.2005
7. Ferreira CG, Span SW, Peters GJ, Kruyt FAE, Giaccone G: Chemotherapy triggers apoptosis in a caspase-8 dependent and mitochondria-controlled manner in the non-small-cell lung cancer cell line H460. Cancer Res 2000, 60: 7133-7141.
8. Fukuda Y, Schuetz JD: ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012, 83: 1073-1083. 10.1016/j.bcp.2011.12.042
9. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2(1):48-58. 10.1038/nrc706
10. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, Lafrenière RG, Cass CE: Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 2001, 61(19):7217-7224.
11. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC: Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 1995, 55(14):3008-3011.
12. Gumina G, Chong Y, Chu CK: l-Nucleosides as Chemotherapeutic Agents. In Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy. Edited by: Peters GJ. Totowa, NJ: Humana Press inc; 2006:173-198.
13. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD: MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 2003, 278(32):29509-29514. 10.1074/jbc.M304059200
14. Guo Y, Kock K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M: Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res 2009, 15: 1762-1769. 10.1158/1078-0432.CCR-08-0442
15. Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002, 29(6 Suppl 20):9-16.23.
16. Honeywell R, Laan AC, Van Groeningen CJ, Strocchi E, Ruiter R, Giaccone G, Peters GJ: The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 847(2):142-152. 10.1016/j.jchromb.2006.09.045
17. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999, 59(11):2532-2535.
18. Hooijberg JH, De Vries NA, Kaspers GJL, Pieters R, Jansen G, Peters GJ: Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006, 58: 1-12.
19. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 2009, 69: 178-184. 10.1158/0008-5472.CAN-08-1420
20. Hussain SA, James ND: The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003, 4(8):489-497. 10.1016/S1470-2045(03)01168-9
21. Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanandam K, Yamada K, Kolesar JM: Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. Int J Oncol 2011, 38(2):513-519.
22. Keepers YP, Pizao PE, Peters GJ, Van Ark-Otte J, Winograd B, Pinedo HM: Comparison of the Sulforhodamine B Protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991, 27: 897-900. 10.1016/0277-5379(91)90142-Z
23. Kruh GD: Introduction to resistance to anticancer agents. Oncogene 2003, 22(47):7262-7264. 10.1038/sj.onc.1206932
24. Kruh GD, Belinsky MG: The MRP family of drug efflux pumps. Oncogene 2003, 22(47):7537-7552. 10.1038/sj.onc.1206953
25. Lage H: An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65(20):3145-3167. 10.1007/s00018-008-8111-5
26. Lemos C, Kathmann I, Giovannetti E, Beliën J, Scheffer GL, Calhau C, Jansen G, Peters GJ: Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Mol Cancer Ther 2009, 8(3):655-664. 10.1158/1535-7163.MCT-08-0768
27. Li Y, Revalde JL, Reid G, Paxton JW: Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol 2011, 68(3):603-610. 10.1007/s00280-010-1515-6
28. Momparler RL: Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. Exp Hematol Oncol 2013, 2(1):20. 10.1186/2162-3619-2-20
29. Noordhuis P, Kazemier K, Kaspers GL, Peters GJ: Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leuk Res 1996, 20(2):127-134. 10.1016/0145-2126(95)00071-2
30. Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari A, Fu L, Cass CE, Chen ZS: Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res 2008, 32: 799-809. 10.1016/j.leukres.2007.09.015
31. Pizao PE, Lyaruu DM, Peters GJ, Van Ark-Otte J, Winograd B, Giaccone G, Pinedo HM: Growth, morphology and chemosensitivity studies on postconfluent cells cultured in “V”-bottomed microtiter plates. Brit J Cancer 1992, 66: 660-665. 10.1038/bjc.1992.333
32. Plunkett W, Gandhi V: Cellular pharmacodynamics of anticancer drugs. Semin Oncol 1993, 20(1):50-63.
33. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O’Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27: 3778-3785. 10.1200/JCO.2008.20.9007
34. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005, 4(5):855-863. 10.1158/1535-7163.MCT-04-0291
35. Ramalingam S, Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008, 13(Suppl 1):5-13.
36. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003, 63(5):1094-1103. 10.1124/mol.63.5.1094
37. Ruiz van Haperen V, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ: Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994, 48(7):1327-1339. 10.1016/0006-2952(94)90554-1
38. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999, 5(9):1048-1051. 10.1038/12487
39. Sigmond J, Honeywell RJ, Postma TJ, Dirven CMF, De Lange SM, Van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman AM, Giaccone G, Peters GJ: Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 2009, 20(1):182-187.
40. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21: 3402-3408. 10.1200/JCO.2003.09.140
41. Veerman G, Ruiz van Haperen VWT, Vermorken JB, Noordhuis P, Braakhuis BJM, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996, 38: 335-342. 10.1007/s002800050492
42. Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH, Borst P: Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002, 62(6):1321-1331. 10.1124/mol.62.6.1321
43. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P: Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003, 278(20):17664-17671. 10.1074/jbc.M212723200
44. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, Van der Born K, De Haas M, Van der Heijden I, Kaspers GJ, Wijnholds J, Jansen G, Peters G, Borst P: The human multidrug resistance protein MRP5 transports folates and can medicte cellular resistance against antifolates. Cancer Res 2005, 65: 4425-4430. 10.1158/0008-5472.CAN-04-2810
45. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000, 97(13):7476-7481. 10.1073/pnas.120159197
46. Yusa K, Oh-hara T, Tsuruo T: Induction of resistance to 1-beta-D-arabinofuranosylcytosine in human H9 cell line by simian immunodeficiency virus. Biochem Biophys Res Commun 1995, 206(2):486-491. 10.1006/bbrc.1995.1069